(Q33491097)
Statements
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies (English)
M J Ratain
L C Platanias
S O'Brien
J P Shaw
S F Williams
J M Baron
K Parker
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference